Cargando…

Alectinib-associated pneumoperitoneum in stage IV non-small cell lung cancer - A case report

INTRODUCTION AND IMPORTANCE: Alectinib, a highly potent, highly selective, brain-penetrant anaplastic lymphoma kinase (ALK) inhibitor is now the first line therapy for patients with metastatic ALK-positive non small cell lung cancer (NSCLC). CASE PRESENTATION: We report a rare case of pneumoperitone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maina, Renee M., Rader, Caroline A., Muenyi, Clarisse S., Battini, Ramakrishna, Zalamea, Nia N., Foretia, Denis A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577531/ https://www.ncbi.nlm.nih.gov/pubmed/36268341 http://dx.doi.org/10.1016/j.amsu.2022.104601

Ejemplares similares

Management and outcomes of chemotherapy-associated pneumoperitoneum in cancer patients: a scoping review protocol
por: Maina, Renee M., et al.
Publicado: (2023)

Retrograde intussusception of jejunojejunostomy after Roux-En-Y gastric bypass leading to small bowel obstruction – Case report of a rare and serious complication
por: Doño, Angel, et al.
Publicado: (2022)

Gallbladder volvulus with gangrenous cholecystitis – A case report
por: Muenyi, Clarisse S., et al.
Publicado: (2022)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Pneumoperitoneum
por: Bertwistle, A. P.
Publicado: (1927)

Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer
por: Kaznatcheev, Artem, et al.
Publicado: (2019)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Pneumoperitoneum
Publicado: (1933)

Pneumoperitoneum
Publicado: (1915)

Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature
por: Ramachandran, P, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

A Case of Advanced Non-Small-Cell Lung Cancer With Response to Alectinib and Favorable Quality of Life
por: Shrestha, Dhan B, et al.
Publicado: (2022)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

Small Bowel Diverticulosis As a Cause of Chronic Pneumoperitoneum
por: Hanna, Mark, et al.
Publicado: (2020)

Massive Pneumoperitoneum
por: Hull, Aicha M, et al.
Publicado: (2010)

Spontaneous Pneumoperitoneum
Publicado: (1933)

Arsenic Disruption of DNA Damage Responses—Potential Role in Carcinogenesis and Chemotherapy
por: Muenyi, Clarisse S., et al.
Publicado: (2015)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
por: Koizumi, Tomonobu, et al.
Publicado: (2016)

Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer
por: Funazo, Tomoko, et al.
Publicado: (2017)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
por: Mu, Lifeng, et al.
Publicado: (2020)

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
por: Chen, Xianmeng, et al.
Publicado: (2022)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma
por: Okumoto, Joe, et al.
Publicado: (2020)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

Chronic Spontaneous Pneumoperitoneum with Pneumatosis Cystoides Intestinalis of the Small and Large Intestine
por: HAKIM, SEIFELDIN, et al.
Publicado: (2020)

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
por: Dziadziuszko, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_40agu6c7i2veehipbbqvserbbj